119 related articles for article (PubMed ID: 37925318)
21. Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children.
Lewnard JA; Givon-Lavi N; Dagan R
Clin Infect Dis; 2020 Nov; 71(8):e289-e300. PubMed ID: 31784753
[TBL] [Abstract][Full Text] [Related]
22. Validation of a Multiplexed Opsonophagocytic Assay for 11 Additional Pneumococcal Serotypes and Its Application to Functional Antibody Evaluation Induced by Pneumococcal Polysaccharide Vaccine.
Cha J; Kim HW; Lee JH; Lee S; Kim KH
J Korean Med Sci; 2018 Dec; 33(51):e340. PubMed ID: 30546285
[TBL] [Abstract][Full Text] [Related]
23. Serotype 3 Antibody Response and Antibody Functionality Compared to Serotype 19A Following 13-Valent Pneumococcal Conjugate Immunization in Children.
Fuji N; Pham M; Kaur R; E Pichichero M
Pediatr Infect Dis J; 2024 Mar; 43(3):294-300. PubMed ID: 38048644
[TBL] [Abstract][Full Text] [Related]
24. Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age.
Kanevsky I; Surendran N; McElwee K; Lei L; Watson W; Pride M; Scully I; Karauzum H; Anderson A; Young M
Vaccine; 2023 Oct; 41(45):6625-6629. PubMed ID: 37793976
[TBL] [Abstract][Full Text] [Related]
25. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.
Thompson A; Lamberth E; Severs J; Scully I; Tarabar S; Ginis J; Jansen KU; Gruber WC; Scott DA; Watson W
Vaccine; 2019 Sep; 37(42):6201-6207. PubMed ID: 31495592
[TBL] [Abstract][Full Text] [Related]
26. A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States.
Fitz-Patrick D; Young M; Scott DA; Scully IL; Baugher G; Peng Y; Jansen KU; Gruber W; Watson W
Hum Vaccin Immunother; 2021 Jul; 17(7):2249-2256. PubMed ID: 33545022
[TBL] [Abstract][Full Text] [Related]
27. Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization.
Madhi SA; Violari A; Klugman KP; Lin G; McIntyre JA; von Gottberg A; Jean-Philippe P; Cotton MF; Adrian P;
Vaccine; 2011 Sep; 29(40):6994-7001. PubMed ID: 21787822
[TBL] [Abstract][Full Text] [Related]
28. Impact of IgM Antibodies on Cross-Protection against Pneumococcal Serogroups 6 and 19 after Immunization with 7-Valent Pneumococcal Conjugate Vaccine in Children.
Cho HK; Park IH; Burton RL; Kim KH
J Korean Med Sci; 2016 Jun; 31(6):950-6. PubMed ID: 27247505
[TBL] [Abstract][Full Text] [Related]
29. Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia.
Takeshita K; Takeuchi N; Takahashi Y; Fukasawa C; Hishiki H; Hoshino T; Ishiwada N; Shimojo N
Hum Vaccin Immunother; 2021 Oct; 17(10):3687-3691. PubMed ID: 34213395
[TBL] [Abstract][Full Text] [Related]
30. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.
Ekström N; Väkeväinen M; Verho J; Kilpi T; Käyhty H
Infect Immun; 2007 Apr; 75(4):1794-800. PubMed ID: 17261612
[TBL] [Abstract][Full Text] [Related]
31. Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study.
Swarthout TD; Henrion MYR; Thindwa D; Meiring JE; Mbewe M; Kalizang'Oma A; Brown C; Msefula J; Moyo B; Mataya AA; Barnaba S; Pearce E; Gordon M; Goldblatt D; French N; Heyderman RS
Lancet Infect Dis; 2022 Dec; 22(12):1737-1747. PubMed ID: 36029796
[TBL] [Abstract][Full Text] [Related]
32. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC
Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
[TBL] [Abstract][Full Text] [Related]
34. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
[TBL] [Abstract][Full Text] [Related]
35. Changes in Streptococcus pneumoniae serotype distribution in invasive disease and nasopharyngeal carriage after the heptavalent pneumococcal conjugate vaccine introduction in Bogotá, Colombia.
Parra EL; De La Hoz F; Díaz PL; Sanabria O; Realpe ME; Moreno J
Vaccine; 2013 Aug; 31(37):4033-8. PubMed ID: 23680440
[TBL] [Abstract][Full Text] [Related]
36. Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese Toddlers.
Gurung M; Bijukchhe SM; Hariri P; Voysey M; Kandasamy R; Thorson S; Maskey P; Pandit R; Shrestha B; Gautam MC; Maharjan M; Lama L; Acharya B; Basi R; K C M; O'Reilly P; Shrestha S; Ansari I; Shah GP; Kelly S; O'Brien KL; Goldblatt D; Kelly DF; Murdoch DR; Pollard AJ; Shrestha S
Pediatr Infect Dis J; 2021 Oct; 40(10):937-943. PubMed ID: 34292271
[TBL] [Abstract][Full Text] [Related]
37. Intranasal Immunization with the Commensal
Shekhar S; Khan R; Schenck K; Petersen FC
Appl Environ Microbiol; 2019 Mar; 85(6):. PubMed ID: 30683742
[No Abstract] [Full Text] [Related]
38. Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen.
Ryman J; Sachs JR; Banniettis N; Weiss T; Ahsman M; Yee KL; Weaver J
Expert Rev Vaccines; 2024; 23(1):467-473. PubMed ID: 38546743
[TBL] [Abstract][Full Text] [Related]
39. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of pneumococcal nasopharyngeal colonization and serotypes circulating in Cameroonian children after the 13-valent pneumococcal conjugate vaccine introduction.
Njuma Libwea J; Gröndahl-Yli-Hannuksela K; Kobela M; Toropainen M; Nyholm O; Ndombo PK; Koulla-Shiro S; Nohynek H; Nuorti JP; Vuopio J; Palmu AA
Int J Infect Dis; 2020 Sep; 98():113-120. PubMed ID: 32562849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
